CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
142 hedge funds and large institutions have $907M invested in Cymabay Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
142
Holders Change
+11
Holders Change %
+8.4%
% of All Funds
3.08%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
26
Increased
48
Reduced
35
Closed
15
Calls
$1.62M
Puts
$852K
Net Calls
+$766K
Net Calls Change
+$970K
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$24.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$23.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.3M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$15.3M |
Top Sellers
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$11.2M |
| 2 |
DM
Deerfield Management
New York
|
-$10.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$8.11M |
| 4 |
NC
Nexthera Capital
New York
|
-$6.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.64M |
